Literature DB >> 28038565

Serum protease activity in chronic kidney disease patients: The GANI_MED renal cohort.

Carmen Wolke1, Alexander Teumer2, Karlhans Endlich3, Nicole Endlich3, Rainer Rettig4, Sylvia Stracke5, Beate Fiene5, Simone Aymanns5, Stephan B Felix6, Anke Hannemann7, Uwe Lendeckel1.   

Abstract

Serum or plasma proteases have been associated with various diseases including cancer, inflammation, or reno-cardiovascular diseases. We aimed to investigate whether the enzymatic activities of serum proteases are associated with the estimated glomerular filtration rate (eGFR) in patients with different stages of chronic kidney disease (CKD). Our study population comprised 268 participants of the "Greifswald Approach to Individualized Medicine" (GANI_MED) cohort. Enzymatic activity of aminopeptidase A, aminopeptidase B, alanyl (membrane) aminopeptidase, insulin-regulated aminopeptidase, puromycin-sensitive aminopeptidase, leucine aminopeptidase 3, prolyl-endopeptidase (PEP), dipeptidyl peptidase 4 (DPP4), angiotensin I-converting enzyme, and angiotensin I-converting enzyme 2 (ACE2) proteases was measured in serum. Linear regression of the respective protease was performed on kidney function adjusted for age and sex. Kidney function was modeled either by the continuous Modification of Diet in Renal Disease (MDRD)-based eGFR or dichotomized by eGFR < 15 mL/min/1.73 m2 or <45 mL/min/1.73 m2, respectively. Results with a false discovery rate below 0.05 were deemed statistically significant. Among the 10 proteases investigated, only the activities of ACE2 and DPP4 were correlated with eGFR. Patients with lowest eGFR exhibited highest DPP4 and ACE2 activities. DPP4 and PEP were correlated with age, but all other serum protease activities showed no associations with age or sex. Our data indicate that ACE2 and DPP4 enzymatic activity are associated with the eGFR in patients with CKD. This finding distinguishes ACE2 and DPP4 from other serum peptidases analyzed and clearly indicates that further analyses are warranted to identify the precise role of these serum ectopeptidases in the pathogenesis of CKD and to fully elucidate underlying molecular mechanisms. Impact statement • Renal and cardiac diseases are very common and often occur concomitantly, resulting in increased morbidity and mortality. Understanding of molecular mechanisms linking both diseases is limited, available fragmentary data point to a role of the renin-angiotensin system (RAS) and, in particular, Ras-related peptidases. • Here, a comprehensive analysis of serum peptidase activities in patients with different stages of chronic kidney disease (CKD) is presented, with special emphasis given to RAS peptidases • The serum activities of the peptidases angiotensin I-converting enzyme 2 and dipeptidyl peptidase 4 were identified as closely associated with kidney function, specifically with the estimated glomerular filtration rate. The findings are discussed in the context of available data suggesting protective roles for both enzymes in reno-cardiac diseases. • The data add to our understanding of pathomechanisms underlying development and progression of CKD and indicate that both enzymes might represent potential pharmacological targets for the preservation of renal function.

Entities:  

Keywords:  Protease activity; angiotensin-converting enzyme 2; chronic kidney disease; dipeptidyl-peptidase IV; estimated glomerular filtration rate; renin–angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 28038565      PMCID: PMC5367655          DOI: 10.1177/1535370216684040

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  64 in total

1.  Expression and activity of ectopeptidases in fibrillating human atria.

Authors:  U Lendeckel; M Arndt; S Wrenger; K Nepple; C Huth; S Ansorge; H U Klein; A Goette
Journal:  J Mol Cell Cardiol       Date:  2001-06       Impact factor: 5.000

2.  Con: Should we abandon the use of the MDRD equation in favour of the CKD-EPI equation?

Authors:  Pierre Delanaye; Hans Pottel; Rossini Botev; Lesley A Inker; Andrew S Levey
Journal:  Nephrol Dial Transplant       Date:  2013-06       Impact factor: 5.992

3.  N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery.

Authors:  Carol P Chong; Wen Kwang Lim; Elena Velkoska; William J van Gaal; Julie E Ryan; Judy Savige; Louise M Burrell
Journal:  Am J Cardiol       Date:  2012-02-28       Impact factor: 2.778

Review 4.  Early recognition and prevention of chronic kidney disease.

Authors:  Matthew T James; Brenda R Hemmelgarn; Marcello Tonelli
Journal:  Lancet       Date:  2010-04-10       Impact factor: 79.321

5.  DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.

Authors:  Jee Eun Lee; Jung Eun Kim; Mi Hwa Lee; Hye Kyoung Song; Jung Yeon Ghee; Young Sun Kang; Hye Sook Min; Hyun Wook Kim; Jin Joo Cha; Jee Young Han; Sang Youb Han; Dae Ryong Cha
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

6.  Gender and age-dependent differences in the bradykinin-degradation within the pericardial fluid of patients with coronary artery disease.

Authors:  Roland Bechtloff; Andreas Goette; Alicja Bukowska; Thilo Kähne; Brigitte Peters; Christof Huth; Carmen Wolke; Uwe Lendeckel
Journal:  Int J Cardiol       Date:  2009-07-09       Impact factor: 4.164

Review 7.  DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis.

Authors:  Dirk Reinhold; Ute Bank; Michael Täger; Siegfried Ansorge; Sabine Wrenger; Anja Thielitz; Uwe Lendeckel; Jürgen Faust; Klaus Neubert; Stefan Brocke
Journal:  Front Biosci       Date:  2008-01-01

8.  Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.

Authors:  Masanori Abe; Osamu Oikawa; Kazuyoshi Okada; Masayoshi Soma
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2014-10-06       Impact factor: 1.636

Review 9.  On the origin of serum CD26 and its altered concentration in cancer patients.

Authors:  Oscar J Cordero; Francisco J Salgado; Montserrat Nogueira
Journal:  Cancer Immunol Immunother       Date:  2009-06-26       Impact factor: 6.968

10.  Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules.

Authors:  Annayya Aroor; Marcin Zuberek; Cornel Duta; Alex Meuth; James R Sowers; Adam Whaley-Connell; Ravi Nistala
Journal:  Int J Mol Sci       Date:  2016-05-20       Impact factor: 5.923

View more
  8 in total

Review 1.  More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.

Authors:  Shreyasi Gupta; Utpal Sen
Journal:  Pharmacol Res       Date:  2019-08-08       Impact factor: 7.658

2.  Temporal changes in soluble angiotensin-converting enzyme 2 associated with metabolic health, body composition, and proteome dynamics during a weight loss diet intervention: a randomized trial with implications for the COVID-19 pandemic.

Authors:  Nicholas Cauwenberghs; Mary Prunicki; František Sabovčik; Dalia Perelman; Kévin Contrepois; Xiao Li; Michael P Snyder; Kari C Nadeau; Tatiana Kuznetsova; Francois Haddad; Christopher D Gardner
Journal:  Am J Clin Nutr       Date:  2021-11-08       Impact factor: 8.472

Review 3.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

4.  Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases.

Authors:  Ayano Kubo; Teruo Hidaka; Maiko Nakayama; Yu Sasaki; Miyuki Takagi; Hitoshi Suzuki; Yusuke Suzuki
Journal:  BMC Nephrol       Date:  2020-09-18       Impact factor: 2.388

Review 5.  Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review.

Authors:  Rodrigo Daza-Arnedo; Jorge-Eduardo Rico-Fontalvo; Nehomar Pájaro-Galvis; Víctor Leal-Martínez; Emilio Abuabara-Franco; María Raad-Sarabia; Juan Montejo-Hernández; María Cardona-Blanco; José Cabrales-Juan; Isabella Uparella-Gulfo; Luis Salgado Montiel
Journal:  Kidney Med       Date:  2021-09-29

6.  The Protective Role of Prolyl Oligopeptidase (POP) Inhibition in Kidney Injury Induced by Renal Ischemia-Reperfusion.

Authors:  Giovanna Casili; Alessio Ardizzone; Rossella Basilotta; Marika Lanza; Alessia Filippone; Irene Paterniti; Emanuela Esposito; Michela Campolo
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

Review 7.  Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials.

Authors:  David M Williams; Asif Nawaz; Marc Evans
Journal:  Diabetes Ther       Date:  2019-12-20       Impact factor: 2.945

8.  Alteration and association between serum ACE2/ angiotensin(1-7)/Mas axis and oxidative stress in chronic kidney disease: A pilot study.

Authors:  Chengqian Shi; Keda Lu; Hong Xia; Peipei Zhang; Bingbing Zhang
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.